Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer Following Investor Relations Lunch


In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), but removed the $33.00 price target.

In the report, Morgan Stanley noted, “We hosted Chuck Triano and Ryan Crowe from Pfizer Investor Relations for lunch in NYC on Thurs. Dec. 12. Discussions focused on Prevnar adult pneumonia prevention trial (CAPiTA), palbociclib breast cancer trial and potential early filing, and business segment reporting and potential breakup. CAPiTA data [is] imminent. The trial has concluded, and Pfizer is analyzing data and will disclose results in a press release in early '14. We assume 80% odds of success because Prevnar has decreased pneumococcal disease since it was introduced. The incremental sales opportunity from a positive CAPiTA could be $2 billion.”

Pfizer closed on Thursday at $30.25.

Latest Ratings for PFE

Jul 2019DowngradesBuyNeutral
Jul 2019DowngradesOverweightEqual-Weight
Jun 2019ReinstatesOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Latest Ratings

HUBBInitiates Coverage On160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morgan Stanley Sees Reasons to Remain Bullish on Canadian Pacific Railway Limited

UPDATE: ITC Holdings Ends Proposed Transaction